RG
SRRA

Redmile Group’s Sierra Oncology, Inc. Common Stock SRRA Stock Holding History

Redmile Group’s Portfolio SRRA Stock Details SRRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-620
Closed -$373K – 60
2015
Q4 		$373K Buy
620
+160
+35% +$108K 0.03% 49
2015
Q3 		$377K Buy
+460
New +$519K 0.03% 53

Other funds holding SRRA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $143M AUM 102.52% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
RIM
RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Redmile Group's SRRA Position: Q1 2016 in Review

Redmile Group sold out of Sierra Oncology, Inc. Common Stock (SRRA) in Q1 2016, closing a stake of 620 shares — an estimated $373K sold.

Redmile Group first reported a position in SRRA in Q3 2015 and held it in 2 quarters. The position peaked at $377K in Q3 2015. 50 funds tracked by Wall St. Rank hold SRRA as of Q1 2016.

  • Redmile Group reported no remaining Sierra Oncology, Inc. Common Stock position as of Q1 2016 after selling out during the quarter.
  • Redmile Group sold 620 Sierra Oncology, Inc. Common Stock shares in Q1 2016, an estimated $373K.
  • Redmile Group first reported a position in Sierra Oncology, Inc. Common Stock in Q3 2015 and held it in 2 quarters.
  • Redmile Group's Sierra Oncology, Inc. Common Stock position peaked at $377K in Q3 2015.
  • 50 funds tracked by Wall St. Rank held Sierra Oncology, Inc. Common Stock as of Q1 2016.

Based on Redmile Group's 13F filing for Q1 2016, filed 16 May 2016.